Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Korro Bio reported preclinical results for KRRO-111, its GalNAc-conjugated RNA-editing therapy for alpha-1 antitrypsin deficiency, showing >95% SERPINA1 mRNA editing in repeat-dose mouse studies. In NSG-PiZ mice, editing reached 96% with total AAT at 172 μM (~6-fold vs. vehicle), and in immunocompetent mice KRRO-111 cut pathogenic hepatic Z-AAT by 95% — addressing both the liver and lung manifestations of AATD. A regulatory submission for KRRO-111 is expected in the first half of 2027, with clinical advancement to follow.
Key figures
- Drug Name
- KRRO-111
- Phase Of Trial
- Preclinical (IND-enabling; regulatory submission expected H1 2027)
- Ec50
- ~1 nM
- Total aat increase
- ~6-fold vs. vehicle (172 μM at Day 57)
- Z aat reduction liver
- 95%
- Editing human hepatocytes
- up to 98%
- Single dose serpina1 editing
- up to 91%
- Serpina1 editing nsg piz mice
- 96%
- M aat share of circulating aat
- up to 93%
- Serpina1 mrna editing repeat dose
- >95%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.